During the opening lecture at the International Conference on Advanced Technologies & Treatments for Diabetes, Melanie Davies, CBE, MB, ChB, MD, FRCP, FRCGP, professor of diabetes medicine at the University of Leicester and an honorary consultant diabetologist at the University Hospitals of Leicester NHS Trust, reviewed how GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy, Novo Nordisk) have changed the way providers approach the treatment of type 2 diabetes and obesity and discussed some of the medications that combine GLP-1 with other molecules
Celik, A., et al., The effects of alpha-lipoic acid on MMP-2 and MMP-9 activities in a rat renal ischemia and re-perfusion model
The incision performed generally from palatal side and if defect reaches to palatal side, incision location should be shifted to buccal side
A survey of convolutional neural networks: analysis, applications, and prospects